. Author manuscript; available in PMC: 2016 Jul 1.

Published in final edited form as: Cancer Chemother Pharmacol. 2015 May 17;76(1):85–96. doi: 10.1007/s00280-015-2768-x

Table 3.

Immediate effects of fludarabine 90 mg/m² upon circulating lymphocyte counts

	Before fludarabine^a	After fludarabine^b
Fludarabine dose number	Dose 1^c	Day after dose 3^c
Time between lymphocyte count and fludarabine dose	4 min (0 – 10.0 h)	23.8 h (20.4 – 43.9 h)
Circulating CD4⁺ (10³ cells/μL)	0.25 ± 0.19 (0.004 – 0.97)	0.08 ± 0.07^d (0 – 0.30)
% decline in circulating CD4⁺	N/A	68 ± 21^e (−47 – 100)
Circulating CD8⁺ (10³ cells/μL)	0.31 ± 0.31 (0 – 1.4)	0.05 ± 0.09^d (0 – 0.76)
% decline in circulating CD8⁺	N/A	82 ± 22^f (−20 – 100)
CD4⁺/CD8⁺ ratio	1.65 ± 1.99 (0.09 – 15)	3.08 ± 2.59^d (0 – 11)

Data presented as mean ± standard deviation;

N=100;

N=99;

Doses 1, 2, 3 administered on HCT days −4, −3, −2, respectively.

P<0.001 using paired t-test of before and after fludarabine data;

One participant’s CD4⁺ count and

two participants’ CD8⁺ counts increased after fludarabine